Suppressive activities of mangiferin on human epithelial ovarian cancer

Zheng Zeng,Caiji Lin,Siwen Wang,Pengfei Wang,Wenwen Xu,Wenqing Ma,Jiali Wang,Qian Xiang,Yiting Liu,Jiaming Yang,Fan Ye,Kaihong Xie,Jian Xu,Yao Luo,Shu-Lin Liu,Huidi Liu
DOI: https://doi.org/10.1016/j.phymed.2020.153267
IF: 6.656
2020-09-01
Phytomedicine
Abstract:<p><em>Background:</em> Epithelial carcinoma is a subtype of ovarian cancers, with the highest lethality among all ovarian cancer subtypes. Hitherto surgical excision combined with chemotherapy has been the most extensively employed method in clinical treatment. However, the disease relapses very frequently, calling for more effective therapies. Mangiferin, a natural compound, has displayed promising anti-cancer activities by <em>in vitro</em> studies, but its therapeutic value in epithelial ovarian cancer treatment, either by <em>in vivo</em> or <em>in vitro</em> studies, remained to be known.</p><p><em>Purpose:</em> This study aimed to determine the suppressive activities of mangiferin on human epithelial ovarian cancer and elucidate the underlying molecular mechanisms.</p><p><em>Study design and methods:</em> We employed the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the crystal violet assay to determine the half maximal inhibitory concentration (IC<sub>50</sub>) values of mangiferin with paclitaxel as a positive control and the inhibitory effects of mangiferin on the proliferation of two human epithelial ovarian cancer cell lines. Wound healing and Transwell assays were used to determine anti-metastastic activities of mangiferin. ES-2 xenograft nude mouse model was used for the <em>in vivo</em> experiments. Western blotting, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) assays were carried out for evaluating the expression level of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9).</p><p><em>Results:</em> In the present study, we demonstrated by both <em>in vitro</em> and <em>in vivo</em> assays that mangiferin suppressed the progress of epithelial ovarian cancer in a dose-dependent manner. In the animals treated with mangiferin, the tumor volume and weight were reduced significantly. Analyses of involved molecular events demonstrated that mangiferin down-regulated the expression of metastasis-associated proteins MMP2 and MMP9.</p><p><em>Conclusion:</em> Mangiferin strongly inhibited the progression of human epithelial ovarian cancer by down-regulating MMP2 and MMP9.</p><dl class="list"><dt class="list-label">•</dt><dd class="list-description"><p>Mangiferin suppresses tumor progression in <em>in-vivo</em> experiments with no side effects.</p></dd><dt class="list-label">•</dt><dd class="list-description"><p>Mangiferin inhibits the metastasis of epithelial ovarian cancer by down-regulating MMP2 and MMP9.</p></dd><dt class="list-label">•</dt><dd class="list-description"><p>Mangiferin reduces the number of epithelial ovarian cancer cells at a relative low concentration and shows a significant inhibitory effect in clear cell carcinoma than paclitaxel in a high concentration.</p></dd></dl>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
What problem does this paper attempt to address?